Jeffrey P. Jones

Jeffrey P. Jones

Auto-generated profile, based on publicly available information

Jeffrey P. Jones

Department of Chemistry, Washington State University, Pullman, Washington

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JJJeffrey P. Jones
Jeffrey P. Jones
MMMichael Mysinger
Michael Mysinger
KKKenneth Ray Korzekwa
Kenneth Ray Korzekwa
Experimental observations suggest that electronic characteristics play a role in the rates of substrate oxidation for cytochrome P450 enzymes. For example, the tendency for oxidation of a certain functional group generally follows the relative stability of the radicals that are formed (e.g., N-dealkylation >O-dealkylation > 2° carbon oxidation > 1° carbon oxidation). In addition, results show that useful correlations between the rates of product formation can be developed using electronic models. In this article, we attempt to determine whether a combined computational model for aromatic and aliphatic hydroxylation can be developed. Toward this goal, we used a combination of experimental data and semiempirical molecular orbital calculations to predicted activation energies for aromatic and aliphatic hydroxylation. The resulting model extends the predictive capacity of our previous aliphatic hydroxylation model to include the second most important group of oxidations, aromatic hydroxylation. The combined model can account for about 83% of the variance in the data for the 20 compounds in the training set and has an error of about 0.7 kcal/mol.

10 November 2008 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
JAJoshua F. Alfaro
Joshua F. Alfaro
JJJeffrey P. Jones
Jeffrey P. Jones

25 July 2016 in Plant Physiology
Verified
Journal Article
Open access
PDF file
AWAlexander M. Walker
Alexander M. Walker
SSSteven A. Sattler
Steven A. Sattler
MRMatthew R Regner
Matthew R Regner
JJJeffrey P. Jones
Jeffrey P. Jones
JRJohn Ralph
John Ralph
CKChulhee Kang
Chulhee Kang
Caffeoyl-CoA 3-O-methyltransferase (CCoAOMT) is an S-adenosyl methionine (SAM)-dependent O-methyltransferase responsible for methylation of the meta-hydroxyl group of caffeoyl-CoA, on the pathway to monolignols with their ring methoxylation status characteristic of guaiacyl or syringyl units in lignin. In order to better understand the unique class of type-2 O-methyltransferases from monocots, we have characterized CCoAOMT from sorghum (Sorghum bicolor) (SbCCoAOMT), including the SAM binary complex crystal structure, steady state enzyme kinetics, isothermal titration calorimetry (ITC), inductively coupled plasma-optical emission spectroscopy (ICP-OES) and molecular docking. Key amino acid residues were validated with site-directed mutagenesis. ITC data indicated a sequential binding mechanism for SbCCoAOMT, wherein SAM binds prior to caffeoyl-CoA, and the enzyme showed allosteric behavior with respect to it. 5-Hydroxyferuloyl-CoA was not a substrate for SbCCoAOMT. We propose a catalytic mechanism in which Lys180 acts as a catalytic base and deprotonates the reactive hydroxyl group of caffeoyl-CoA. This deprotonation is facilitated by the coordination of the reactive hydroxyl group by Ca2+ in the active site, lowering the pKa of the 3′-OH group. Collectively, these data give a new perspective on the catalytic mechanism of CCoAOMTs and provide a basis for the functional diversity exhibited by type-2 plant OMTs that contain a unique insertion loop (residues 208-231) conferring affinity for phenylpropanoid-CoA thioesters.

1 December 2011 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
UDUpendra P. Dahal
Upendra P. Dahal
JJJeffrey P. Jones
Jeffrey P. Jones
JDJohn A. Davis
John A. Davis
DRDan A. Rock
Dan A. Rock
Identification and quantification of the metabolites of drugs and drug candidates are routinely performed using liquid chromatography-mass spectrometry (LC-MS). The best practice is to generate a standard curve with the metabolite versus the internal standard. However, to avoid the difficulties in metabolite synthesis, standard curves are sometimes prepared using the substrate, assuming that the signal for substrate and the metabolite will be equivalent. We have tested the errors associated with this assumption using a series of very similar compounds that undergo common metabolic reactions using both conventional flow electrospray ionization LC-MS and low-flow captive spray ionization (CSI) LC-MS. The differences in standard curves for four different types of transformations (O-demethylation, N-demethylation, aromatic hydroxylation, and benzylic hydroxylation) are presented. The results demonstrate that the signals of the substrates compared with those of the metabolites are statistically different in 18 of the 20 substrate-metabolite combinations for both methods. The ratio of the slopes of the standard curves varied up to 4-fold but was slightly less for the CSI method.

1 December 2011 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JBJohn T. Barr
John T. Barr
JJJeffrey P. Jones
Jeffrey P. Jones
During the course of our research efforts to understand the kinetics of human aldehyde oxidase as a xenobiotic-clearing enzyme, we investigated the effect of eight different inhibitors on the oxidation of the probe substrate phthalazine. Saturation kinetic parameters for phthalazine oxidation in human liver cytosol were found to be the following: Km = 8.0 ± 0.4 μM and Vmax = 4.3 ± 0.1 nmol · min−1 · mg protein−1. Inhibitory potency of the inhibitors tested ranged from 0.1 to 5 μM. Of the eight different inhibitor compounds tested, seven were observed to inhibit through a mixed mode and one through a strictly competitive mode. A ratio of the Kii and Kis values was used to assess the relative competitiveness of each inhibitor. For the mixed inhibitors, the mode of inhibition varied from mostly uncompetitive to predominantly competitive (Kii/Kis values ranging from 0.1 to 15). The implications for potential drug-drug interactions and inhibition mechanism are discussed. We found two inhibitors, clozapine and chlorpromazine, that have a moderate predicted risk of drug-drug interactions based on the Ki value relative to the inhibitor concentration in human plasma, having a calculated [I]/Ki value of 0.4 and 0.8, respectively.

1 December 2009 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JAJoshua F. Alfaro
Joshua F. Alfaro
CJCarolyn A. Joswig-Jones
Carolyn A. Joswig-Jones
WOWenyun Ouyang
Wenyun Ouyang
JNJoseph Nichols
Joseph Nichols
GCGregory J. Crouch
Gregory J. Crouch
JJJeffrey P. Jones
Jeffrey P. Jones
Human aldehyde oxidase 1 (AOX1) has been subcloned into a vector suitable for expression in Escherichia coli, and the protein has been expressed. The resulting protein is active, with sulfur being incorporated in the molybdopterin cofactor. Expression levels are modest, but 1 liter of cells supplies enough protein for both biochemical and kinetic characterization. Partial purification is achieved by nickel affinity chromatography through the addition of six histidines to the amino-terminal end of the protein. Kinetic analysis, including kinetic isotope effects and comparison with xanthine oxidase, reveal similar mechanisms, with some subtle differences. This expression system will allow for the interrogation of human aldehyde oxidase structure/function relationships by site-directed mutagenesis and provide protein for characterizing the role of AOX1 in drug metabolism.